Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials
暂无分享,去创建一个
G. Garcia-Manero | T. Kadia | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | N. Pemmaraju | N. Jain | N. Short | S. Loghavi | G. Tang | M. Brandt | S. Pierce | K. Sasaki | H. Kantarjian | C. Rausch | Kunhwa Kim | M. Yilmaz | M. Konopleva
[1] J. Welch,et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. , 2020, The Lancet. Haematology.
[2] M. Tallman,et al. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis , 2020, Transfusion.
[3] H. Einsele,et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? , 2020, Blood.
[4] M. Konopleva,et al. Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML). , 2020 .
[5] M. Tormo,et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multi-center, international study , 2020, Leukemia.
[6] H. Kantarjian,et al. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia , 2018, Haematologica.
[7] B. Ko,et al. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor‐risk factor in de novo acute myeloid leukemia patients , 2018, European journal of haematology.
[8] Tae Kon Kim,et al. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey* , 2018, Leukemia & lymphoma.
[9] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[10] J. Cortes,et al. Mutations in AML: prognostic and therapeutic implications. , 2016, Hematology. American Society of Hematology. Education Program.
[11] C. Abboud,et al. Leukostasis in adult acute hyperleukocytic leukemia: a clinician's digest , 2016, Hematological oncology.
[12] C. Mason,et al. Genetic and epigenetic heterogeneity in acute myeloid leukemia. , 2016, Current opinion in genetics & development.
[13] H. Kantarjian,et al. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. , 2015, JAMA oncology.
[14] G. Ehninger,et al. How I treat hyperleukocytosis in acute myeloid leukemia. , 2015, Blood.
[15] J. Beyene,et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. , 2014, Leukemia research.
[16] H. Kantarjian,et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.
[17] C. Récher,et al. Early ICU Admission Of Newly Diagnosed Acute Myeloid Leukemia With No Organ Failure , 2013 .
[18] G. Laurent,et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. , 2013, Blood.
[19] H. Kantarjian,et al. Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients , 2012, Modern Pathology.
[20] J. Harbott,et al. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. , 2010, Blood.
[21] E. Estey,et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. , 2009, Blood.
[22] F. Ricci,et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. , 2008, Leukemia research.
[23] D. Horsman,et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia , 2006, Leukemia & lymphoma.
[24] Yu Shen,et al. Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival , 2001, Leukemia & lymphoma.
[25] J. Armitage,et al. Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. , 1977, Archives of internal medicine.